MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines

Table 2 Dysregulated microRNAs in resistant cells: quantitative real-time polymerase chain reaction validation

	Cisplatin resistant EAC	Cisplatin resistant ESCC	5-FU resistant EAC	5-FU resistant ESCC
Significantly dysregulated miRNAs in resistant variants	miR-455-3p (-3.06)	miR-130a-3p (1.70)	miR-378a-3p (-3.58)	miR-935 (-2.29)
	miR-200b-3p (-2.46)		miR-192-5p (-2.32)	miR-550a-3p (2.21)
	let-7e-5p (-2.44)		miR-210-3p (-2.19)	miR-125a-5p (-2.20)
	miR-181b-5p (-1.88)		miR-194-5p (-2.01)	miR-1226-3p (-2.12)
	miR-125a-5p (-1.79)		miR-222-3p (1.85)	miR-99b-5p (-1.88)
	miR-181a-5p (-1.63)		miR-17-3p (-1.83)	miR-18a-3p (-1.75)
	miR-200b-5p (-1.63)		miR-193b-3p (1.54)
	miR-31-5p (-1.58)		miR-31-5p (1.40)
	miR-200a-3p (-1.57)		miR-27b-3p (1.36)
	miR-638 (1.55)
	miR-191-5p (1.42)

Final quantitative real-time polymerase chain reaction validation results for the different chemotherapy resistant cell lines, including dysregulated miRNAs and fold changes in expression compared to chemotherapy sensitive controls. All listed miRNAs were significantly dysregulated compared to controls. FU: 5-FU resistant cells; EAC: Esophageal adenocarcinoma cells; ESCC: Esophageal squamous cell carcinoma cells.